MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgag155

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2026

Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism.

Ao Linjun, Noordam Raymond, Trompet Stella, van Vliet Nicolien A, Sattar Naveed, Rodondi Nicolas, Moutzouri Elisavet, Atighetchi Sarah, Kearney Patricia M, Quinn Terry, Jukema J Wouter, Gussekloo Jacobijn, Mooijaart Simon P, Willems van Dijk Ko, Poortvliet Rosalinde K E, van Heemst Diana

СтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

CONTEXT: Randomized controlled trials (RCTs) found no cardioprotective effects of levothyroxine therapy in older adults with subclinical hypothyroidism.

OBJECTIVE

The aim of this study was to assess levothyroxine effects on cardiometabolic biomarkers, which may serve as more sensitive treatment indicators.

DESIGN

Post-hoc analysis using (baseline and 12-month) data from two double-blind RCTs in older adults (≥65 years) with subclinical hypothyroidism.

MAIN OUTCOME MEASURE(S): Cardiometabolic biomarkers included seven clinically relevant lipid measures (apolipoprotein B (ApoB), total cholesterol (Total-C), non-high-density lipoprotein cholesterol (non-HDL-C), remnant cholesterol (RC), low-density lipoprotein cholesterol (LDL-C), HDL-C, and triglycerides (TG)) and 167 standardized metabolomic measures from nuclear magnetic resonance. Analyses were additionally stratified by baseline TSH levels.

RESULTS

Among 286 included participants (48% women; median age 75 [70, 82] years; median baseline TSH 6.44 [5.36, 7.81] mIU/L), 142 were randomized to levothyroxine. Overall, levothyroxine showed no effects on ApoB (-0.03 [95% CI: -0.07, 0.00] g/L), Total-C (-0.17 [-0.34, 0.00] mmol/L), non-HDL-C (-0.15 [-0.31, 0.00] mmol/L), RC (-0.09 [-0.16, -0.01] mmol/L), LDL-C (-0.07 [-0.15, 0.02] mmol/L), and TG (-0.07 [-0.15, 0.01] mmol/L). In participants with baseline TSH ≥10 mIU/L (n = 27), potentially beneficial changes (P < .05, but not significant after multiple-testing correction) were observed for all clinically relevant lipids except HDL-C, as well as for ApoB-containing lipoproteins, VLDL size, and fatty acids.

CONCLUSION

In older adults with subclinical hypothyroidism, levothyroxine treatment showed no effects on cardiometabolic biomarkers, although potentially favorable changes in lipids and lipoproteins were observed for individuals with baseline TSH ≥10 mIU/L.

Для цитирования: Ao Linjun, Noordam Raymond, Trompet Stella, van Vliet Nicolien A, Sattar Naveed, Rodondi Nicolas, Moutzouri Elisavet, Atighetchi Sarah, Kearney Patricia M, Quinn Terry, Jukema J Wouter, Gussekloo Jacobijn, Mooijaart Simon P, Willems van Dijk Ko, Poortvliet Rosalinde K E, van Heemst Diana. Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism.. The Journal of clinical endocrinology and metabolism. 2026. DOI: 10.1210/clinem/dgag155.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.